Long-Term Improvement in the Patient-Reported Outcomes of Rectal Bleeding, Stool Frequency, and Health-Related Quality of Life with Tofacitinib in the Ulcerative Colitis OCTAVE Clinical Program

BACKGROUND: Tofacitinib is an oral small molecule Janus kinase inhibitor for the treatment of ulcerative colitis (UC). The tofacitinib OCTAVE clinical program included phase III induction (OCTAVE Induction 1 and 2) and maintenance (OCTAVE Sustain) studies, and an open-label, long-term extension stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Hudesman, David P., Torres, Joana, Salese, Leonardo, Woolcott, John C., Mundayat, Rajiv, Su, Chinyu, Mosli, Mahmoud H., Allegretti, Jessica R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911479/
https://www.ncbi.nlm.nih.gov/pubmed/36336750
http://dx.doi.org/10.1007/s40271-022-00603-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9911479/
https://www.ncbi.nlm.nih.gov/pubmed/36336750
http://dx.doi.org/10.1007/s40271-022-00603-w

Ejemplares similares